Literature DB >> 12707291

Blood pressure predicts risk of developing end-stage renal disease in men and women.

Masahiko Tozawa1, Kunitoshi Iseki, Chiho Iseki, Kozen Kinjo, Yoshiharu Ikemiya, Shuichi Takishita.   

Abstract

Blood pressure as a risk factor for development of end-stage renal disease has not been fully studied, particularly in women. We studied the development of end-stage renal disease from 1983 through 2000 in 98 759 subjects, 46 881 men and 51 878 women, 20 to 98 years of age, who were screened in 1983 in Okinawa, Japan. Data for all dialysis patients registered from 1983 to 2000 in Okinawa were used to identify the screened subjects in whom end-stage renal disease developed. In follow-up, 400 subjects, 231 men and 169 women, had end-stage renal disease. Age, body mass index, and adjusted relative risk for systolic and diastolic blood pressure for both men and women were measured. When these results were compared with an optimal blood pressure, the relative risk of development of end-stage renal disease for those with high-normal blood pressure and hypertension were significant in both men and women. Hypertension is a significant risk factor for development of end-stage renal disease not only in men but also in women. Control of blood pressure within normal levels should be stressed as a strategy to prevent end-stage renal disease in both men and women.

Entities:  

Mesh:

Year:  2003        PMID: 12707291     DOI: 10.1161/01.HYP.0000069699.92349.8C

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  83 in total

1.  Home blood pressure level and decline in renal function among treated hypertensive patients: the J-HOME-Morning Study.

Authors:  Kazuki Ishikura; Taku Obara; Masahiro Kikuya; Michihiro Satoh; Miki Hosaka; Hirohito Metoki; Hidekazu Nishigori; Nariyasu Mano; Masaaki Nakayama; Yutaka Imai; Takayoshi Ohkubo
Journal:  Hypertens Res       Date:  2015-10-29       Impact factor: 3.872

2.  Impact of kidney function and urinary protein excretion on intima-media thickness in Japanese patients with type 2 diabetes.

Authors:  Yusuke Nakade; Tadashi Toyama; Kengo Furuichi; Shinji Kitajima; Yoshiyasu Miyajima; Mihiro Fukamachi; Akihiro Sagara; Yasuyuki Shinozaki; Akinori Hara; Miho Shimizu; Yasunori Iwata; Hiroyasu Oe; Mikio Nagahara; Hiroshi Horita; Yoshio Sakai; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2015-02-03       Impact factor: 2.801

3.  Age-related renal disease in female Dahl salt-sensitive rats is attenuated with 17 beta-estradiol supplementation by modulating nitric oxide synthase expression.

Authors:  Christine Maric; Qin Xu; Kathryn Sandberg; Carmen Hinojosa-Laborde
Journal:  Gend Med       Date:  2008-06

4.  Black-White Difference in the Impact of Long-Term Blood Pressure From Childhood on Adult Renal Function: The Bogalusa Heart Study.

Authors:  Yinkun Yan; Tao Zhang; Shengxu Li; Yang Liu; Lydia Bazzano; Jiang He; Jie Mi; Wei Chen
Journal:  Am J Hypertens       Date:  2018-11-13       Impact factor: 2.689

5.  Optimizing blood pressure control in patients with chronic kidney disease.

Authors:  Biff F Palmer; Andrew Z Fenves
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-07

Review 6.  Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness.

Authors:  Gary L Schwartz
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

7.  Heart rate as a risk factor for developing chronic kidney disease: longitudinal analysis of a screened cohort.

Authors:  Taku Inoue; Kunitoshi Iseki; Chiho Iseki; Yusuke Ohya; Kozen Kinjo; Shuichi Takishita
Journal:  Clin Exp Nephrol       Date:  2009-05-15       Impact factor: 2.801

Review 8.  [Hypertension and the kidney].

Authors:  Katharina Hohenstein; Bruno Watschinger
Journal:  Wien Med Wochenschr       Date:  2008

9.  Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Authors:  Takashi Wada; Tatsuo Hosoya; Daisuke Honda; Ryusuke Sakamoto; Kazutaka Narita; Tomomitsu Sasaki; Daisuke Okui; Kenjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2018-01-25       Impact factor: 2.801

10.  Progression of renal dysfunction in patients with cardiovascular disease.

Authors:  Yasunobu Hirata; Arihiro Kiyosue; Masao Takahashi; Hiroshi Satonaka; Daisuke Nagata; Masataka Sata; Etsu Suzuki; Ryozo Nagai
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.